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Background-—Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disease characterized by varying degrees of left
ventricular outﬂow tract obstruction. In a large cohort, we compare the outcomes among 3 different hemodynamic groups.
Methods and Results-—We prospectively enrolled patients fulﬁlling standard diagnostic criteria for HCM from January 2005 to June
2015. Detailed phenotypic characterization, including peak left ventricular outﬂow tract pressure gradients at rest and after
provocation, was measured by echocardiography. The primary outcome was a composite cardiovascular end point, which included
new-onset atrial ﬁbrillation, new sustained ventricular tachycardia/ventricular ﬁbrillation, new or worsening heart failure, and
death. The mean follow-up was 3.42.8 years. Among the 705 patients with HCM (mean age, 5215 years; 62% men), 230 with
obstructive HCM were older and had a higher body mass index and New York Heart Association class. The 214 patients with
nonobstructive HCM were more likely to have a history of sustained ventricular tachycardia/ventricular ﬁbrillation and implantable
cardioverter deﬁbrillator implantation. During follow-up, 121 patients experienced a composite cardiovascular end point. Atrial
ﬁbrillation occurred most frequently in the obstructive group. Patients with nonobstructive HCM had more frequent sustained
ventricular tachycardia/ventricular ﬁbrillation events. In multivariate analysis, obstructive (hazard ratio, 2.80; 95% conﬁdence
interval, 1.64–4.80) and nonobstructive (hazard ratio, 1.94; 95% conﬁdence interval, 1.09–3.45) HCM were associated with more
adverse events compared with labile HCM.
Conclusions-—Nonobstructive HCM carries notable morbidity, including a higher arrhythmic risk than the other HCM groups.
Patients with labile HCM have a relatively benign clinical course. Our data suggest detailed sudden cardiac death risk stratiﬁcation
in nonobstructive HCM and monitoring with less aggressive management in labile HCM. ( J Am Heart Assoc. 2018;7:e006657.
DOI: 10.1161/JAHA.117.006657.)
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H ypertrophic cardiomyopathy (HCM) is one of the mostcommon inherited cardiac diseases, characterized by
ventricular hypertrophy, myoﬁber disarray, and ﬁbrosis.1–3
Clinical manifestations include exercise intolerance, heart
failure (HF), and cardiac arrhythmias, including sudden death.4
Approximately two thirds of patients with HCM demonstrate a
dynamic left ventricular outﬂow tract (LVOT) gradient at rest
or with provocation. This obstruction is thought to be the
primary driver of symptoms.5,6 A resting LVOT gradient
≥30 mm Hg is a strong independent predictor for progression
of HF and death.7,8 Conversely, nonobstructive HCM (rest/
stress gradient <30 mm Hg) is generally managed conserva-
tively. These concepts were reiterated in recent guidelines
and expert reviews, which summarized that a “majority of
non-obstructive HCM patients experience a relatively stable
clinical course without signiﬁcant symptoms, high-risk proﬁle,
or the necessity of major treatment options (p. 94).”4
Novel imaging methods have documented that, in addition
to LVOT gradients, HCM is associated with myocardial
ﬁbrosis,2 microvascular ischemia,3,9 and abnormal cardiac
mechanics,10 which may be important contributors to clinical
adverse events.2,11 We recently demonstrated that more
patients with nonobstructive HCM had a large scar burden (on
magnetic resonance imaging) and higher rates of microvas-
cular ischemia (by positron emission tomography).12 Thus,
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there are lines of evidence suggesting that nonobstructive
HCM may not be pathophysiologically benign. The wider
question that has not yet been well addressed is whether the
current hemodynamics-based 3 HCM classiﬁcation (nonob-
structive, labile, and obstructive) confers any distinctive
clinical risk.
In this study, we examined the long-term outcomes in
patients with HCM, stratiﬁed by rest/stress outﬂow tract
hemodynamics, in a relatively large, well-characterized, single-
center cohort.
Methods
Study Population and Data Collection
The data, analytic methods, and study materials have been
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.12 This HCM
Registry study was approved by the Institutional Review Board
of the Johns Hopkins Hospital, and patients signed informed
consent for any procedures performed only for research
purposes. Patients were prospectively enrolled in the Johns
Hopkins HCM Registry from January 2005 to June 2015 at
their ﬁrst visit if they met the standard diagnostic criteria for
HCM, which was unexplained LV hypertrophy with maximal
wall thickness ≥15 mm in the absence of other systemic or
explainable cause. Patients with a previous history of septal
reduction therapy (septal myectomy or alcohol septal abla-
tion) were excluded. Patients with reduced (<50%) ejection
fraction were also excluded, because end-stage cardiomy-
opathy is associated with higher risk. Retrospective analysis
of data was performed in this study. The latest clinical
assessment was obtained by clinic visit, mail, or telephone
contact up to June 30, 2016. Patients were censored at
development of any of the preidentiﬁed end points or 1 day
before septal reduction therapy. Clinical information was
collected, as previously reported.13
Conventional and Stress Echocardiography
Transthoracic echocardiography was performed using a GE
Vivid 7 or E-9 ultrasound machine (GE Ultrasound, Milwaukee,
WI) with a multifrequency phased-array transducer. Conven-
tional biplane LV volume and LV ejection fraction were
measured by the modiﬁed Simpson rule, according to
previously published guidelines.14 Doppler measurements
consisted of mitral inﬂow early diastole (E) and atrial
contraction waves. LVOT pressure gradients were measured
in the apical views by continuous-wave Doppler echocardio-
graphy under resting conditions and during provocative
maneuvers, including Valsalva, treadmill exercise, and/or
amyl nitrite inhalation, to elicit latent obstruction, as previ-
ously reported.13,15,16 Tissue Doppler peak early diastolic
wave (e0) was derived from the apical 4-chamber view at the
basal level of the septal wall and was used to calculate E/e0
ratio.17 After measuring peak resting and stress pressure
gradients, classiﬁcation of HCM was established as nonob-
structive (<30 mm Hg at rest and stress), labile (<30 mm Hg
at rest and ≥30 mm Hg with stress), and obstructive
(≥30 mm Hg at rest and stress).18,19
After completion of conventional echocardiography,
patients without contraindications underwent a treadmill
exercise test. Those with active angina, decompensated HF,
uncontrolled arrhythmias, hemodynamic instability, severe
hypertension/hypotension, and inability to walk on a treadmill
were excluded. Standard Bruce protocol was implemented in
all subjects, except those with a history of poor functional
status, in which case we used a modiﬁed Bruce or Naughton
protocol. All subjects were monitored for symptoms, heart
rate, blood pressure, and continuous 12-lead electrocardiog-
raphy. Abnormal blood pressure response was considered as
an increase of <20 mm Hg in systolic blood pressure (SBP)
from resting state to peak exercise, an initial increase in SBP
with a subsequent decrease of >20 mm Hg compared with
the SBP value at peak exercise, or a continuous decrease in
SBP throughout the exercise test of >20 mm Hg compared
with SBP at rest.20,21 After exercise, patients were immedi-
ately placed in the left lateral decubitus position, and peak
Clinical Perspective
What Is New?
• Although all clinicians follow a new hemodynamic classiﬁ-
cation for hypertrophic cardiomyopathy (HCM), there are no
long-term data of prognosis using this new classiﬁcation.
• The study provides clinical outcomes, not just mortality,
among patients with different hemodynamic classiﬁcations.
• Our results from a large cohort suggest that patients with
nonobstructive HCM have a high risk of arrhythmic and
sudden death events.
• Conversely, patients with labile HCM have a relatively
benign clinical course.
What Are the Clinical Implications?
• Despite low annual mortality rates, patients with nonob-
structive HCM have high rates of adverse clinical events,
almost equivalent to obstructive HCM.
• Patients with nonobstructive HCM warrant thorough vetting,
with a focus on the need for deﬁbrillator therapy.
• Patients with labile HCM have the best prognosis and may
need less aggressive management.
• Routine exercise stress echocardiography in all patients
with HCM and particularly in those with resting gradients
<30 mm Hg may be suggested, regardless of symptoms.
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instantaneous LV outﬂow tract velocities were measured
again, as previously mentioned, in the apical view.
Deﬁnition of Cardiovascular Events and Follow-
Up
A composite cardiovascular end point was prespeciﬁed as
the primary outcome variable. The components of this
composite end point were the following common complica-
tions of HCM: new-onset atrial ﬁbrillation (AF); new
sustained (≥30 seconds) ventricular tachycardia/ventricular
ﬁbrillation (VT/VF), with or without appropriate implantable
cardioverter deﬁbrillator (ICD) discharge; new-onset or
worsening HF (deﬁned as worsening of New York Heart
Association [NYHA] functional class to class III or IV)
requiring hospitalization; and all-cause mortality. If an
outcome event was experienced before enrollment and
recurred during follow-up, that particular event was not
considered as an outcome. Arrhythmic outcomes (AF and
VT/VF) were recorded by reviewing clinical visit documents,
Holter monitoring, and ICD interrogation reports. New-onset
or worsening HF at NYHA class III or IV had to be
documented in outpatient visits or in-hospital medical
records. All-cause mortality statistics for the study popula-
tions were obtained by linking our database to the Social
Security Death Index, with a follow-up duration of up to
10 years. All events were clinically adjudicated by 1 of 2
HCM clinical experts (T.P.A. and M.R.A.), who also reviewed
raw data and electronic documentation of all arrhythmic
events. Any conﬂict was resolved by repeated review of the
documentation and consensus between the experts. During
follow-up, patients who underwent septal reduction therapy
before any adverse event were considered as censored
1 day before septal reduction therapy. Patients who
remained event free were censored on June 30, 2016, with
the longest duration being 10 years.
Statistical Analysis
Descriptive statistics were performed on patient demo-
graphics, hemodynamics, conventional echocardiographic
parameters, and outcomes, stratiﬁed by each category of
HCM. Data distribution was evaluated with kernel density
plots and the Shapiro-Wilk test for normality. Continuous
variables are presented as meanSD, and categorical
variables are presented as the total number and percent-
age. Comparison of continuous variables across groups was
performed using ANOVA if normally distributed or Kruskal-
Wallis test if not normally distributed, and comparison of
categorical variables was performed using the Fisher exact
test. Kaplan-Meier analysis of the primary end point was
analyzed for the time of enrollment to the ﬁrst composite
cardiovascular event, with the signiﬁcance based on the
log-rank test. The Cox proportional hazards model was used
to adjust for possible confounders of composite outcomes.
Variables that were statistically signiﬁcant in the univariate
analysis were enrolled in a multivariate model, which
included age, sex, baseline NYHA functional class, history
of sustained VT/VF, left atrial (LA) diameter, and E/e0.
P<0.05 was considered statistically signiﬁcant. The analyses
were performed using STATA software, version 14 (Stata-
Corp LP, College Station, TX).
Results
After excluding 13 patients for previous myectomy and 16 for
LV ejection fraction <50% (9 nonobstructive, 4 labile, and 3
obstructive), we analyzed 705 patients (mean age,
52.715.1 years at study enrollment; 62% men) with com-
plete follow-up data (mean duration of follow-up,
3.42.8 years).
Clinical Features
Among the 705 patients, 214 (30%) had nonobstructive HCM,
whereas 261 (37%) had labile and 230 (33%) had obstructive
HCM. The clinical and echocardiographic characteristics are
summarized in Table 1. All continuous variables were nor-
mally distributed. Patients with obstructive HCM were older,
had a higher body mass index, and were associated with
higher frequencies of female sex and comorbidities (hyper-
tension, dyslipidemia, and dyspnea), reﬂecting a more
advanced NYHA class. Among risk factors for sudden cardiac
death, patients with obstructive HCM had more prevalent
abnormal blood pressure response during exercise. Patients
with nonobstructive HCM were associated with a higher
frequency of history of nonsustained VT/VF and ICD
implantation.
Echocardiography
Echocardiographic features are summarized in Table 2. By
deﬁnition, patients with obstructive HCM had the highest rest
and stress LVOT pressure gradients. Mean rest gradient in the
obstructive group was 6631 mm Hg, and stress gradient
was 11845 mm Hg. Although LV ejection fraction was
similar across the 3 groups, patients with obstructive HCM
had more advanced diastolic dysfunction, as demonstrated by
a larger LA diameter, a lower E/atrial contraction ratio, and a
higher E/e0 ratio. Of the study patients, 644 (91%) underwent
stress echo with treadmill exercise. Patients with obstructive
HCM were associated with worst exercise capacity and least
increment in peak exercise heart rate.
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Composite and Speciﬁc Outcomes
During a 2407 person-year follow-up, 121 patients (17%)
experienced a composite cardiovascular end point, including
38 new cases of AF, 27 new cases of sustained VT/VF (10
were resuscitated successfully, and 17 had appropriate ICD
shock), 38 cases of HF, and 18 deaths. Nonobstructive and
obstructive groups had similar cumulative incidence of
composite events, whereas the labile group had the lowest
cumulative incidence (nonobstructive:labile:obstructive,
20%:8%:24%; P<0.001).
There were differences in the incidence of individual end
points when segregated by hemodynamic subgroups of HCM
and by the speciﬁc outcome. When analyzing by HCM
subgroups, sustained VT/VF was the most common event
in nonobstructive HCM (37%), followed by HF and death
(Figure 1A). In the labile group, HF, AF, and sustained VT/VF
were the most common events (Figure 1B). In contrast, AF
accounted for almost half of overall events in obstructive
group, whereas sustained VT/VF incidence was only 13%
(Figure 1C).
When we focused on speciﬁc outcomes, obstructive HCM
had the highest risk of developing AF (log-rank P<0.001)
(Figure 2A and Table 3). For sustained VT/VF, patients with
labile obstruction had the best event-free survival, followed by
the obstructive group (log-rank P=0.004) (Figure 2B). Labile
Table 1. Baseline Characteristics in Patients Stratiﬁed by HCM Classiﬁcation
Characteristics
Nonobstructive
HCM (N=214)
Labile HCM
(N=261)
Obstructive
HCM (N=230) P Value
Age, y 49.615.9 52.015.3 56.313.3 <0.001
Male sex, n (%) 134 (63) 181 (69) 121 (53) 0.001
BMI, kg/m2 28.75.4 29.76.6 30.16.6 0.039
NYHA functional class, n (%) <0.001
I 138 (65) 157 (60) 94 (41)
II–III 76 (35) 104 (40) 136 (59)
Risk factor for SCD
Syncope, n (%) 37 (17) 53 (20) 42 (18) 0.687
Family history of SCD, n (%) 56 (26) 65 (25) 54 (24) 0.790
NSVT, n (%) 36 (17) 26 (10) 17 (7) 0.005
ABPR, n (%) 50 (25) 82 (33) 87 (43) 0.001
IVS ≥30 mm, n (%) 23 (11) 15 (6) 15 (7) 0.097
No. of risk factors 1.00.9 0.90.9 1.00.9 0.641
Comorbidity, n (%)
Atrial fibrillation 38 (18) 38 (15) 36 (16) 0.633
Hypertension 83 (39) 139 (53) 125 (55) 0.001
Diabetes mellitus 21 (10) 35 (13) 19 (8) 0.165
Dyslipidemia 85 (40) 124 (48) 126 (55) 0.007
Coronary artery disease 17 (8) 26 (10) 22 (10) 0.743
Stroke 5 (2) 6 (2) 11 (5) 0.212
ICD implantation 26 (12) 13 (5) 16 (7) 0.012
Family history of HCM, n (%) 65 (31) 38 (15) 30 (13) <0.001
Medications, n (%)
b Blocker 145 (68) 179 (69) 182 (79) 0.012
Calcium channel blocker 45 (21) 74 (28) 79 (34) 0.008
RAS blockade 38 (18) 50 (19) 38 (17) 0.749
Disopyramide 3 (1) 11 (4) 8 (1) 0.203
Data are given as meanSD unless otherwise indicated. ABPR indicates abnormal blood pressure response; BMI, body mass index; HCM, hypertrophic cardiomyopathy; ICD, implantable
cardioverter deﬁbrillator; IVS, interventricular septum; NSVT, nonsustained ventricular tachycardia; NYHA, New York Heart Association; RAS, angiotensin-converting enzyme inhibitor and
angiotensin II receptor blocker; and SCD, sudden cardiac death.
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and obstructive HCM subgroups experienced most of their
sustained VT/VF events within 5 years of enrollment, with
signiﬁcantly lower rates of sustained VT/VF beyond 5 years,
suggesting some clinical stabilization. In contrast, the nonob-
structive group continued to experience frequent malignant
arrhythmic events; the sustained VT/VF-free survival tracing
declined progressively over time, resulting in the overall worst
VT/VF-free survival across the 3 subgroups. Event-free
survival rates for HF and all-cause death were similar across
the 3 subgroups (Figure 2C and 2D).
We performed additional analysis of the labile HCM group
that demonstrated the best event-free survival. Of 261
patients with labile HCM, 103 (39%) had NYHA class II to III
symptoms, and 158 (61%) were asymptomatic (NYHA class I).
There were 14 composite events in symptomatic patients,
including 5 cases of new-onset AF, 8 cases of new-onset or
worsening HF, and 1 death. On the other hand, asymptomatic
patients had 8 composite events, with 1 case of new-onset
AF, 4 cases of new-onset VT/VF, 1 case of new-onset or
worsening HF, and 2 deaths. Symptomatic patients had
signiﬁcantly higher risks of HF (P=0.006) and composite end
points (P=0.028). Examining only the 391 asymptomatic
patients in our study, labile HCM still carried a better
prognosis than the other 2 groups (nonobstructive versus
labile versus obstructive, 15% versus 5% versus 26%;
P<0.001).
For composite cardiovascular outcomes, patients with
labile HCM had the best, and patients with obstructive
HCM had the worst, event-free survival at the end of follow-
up (Figure 2E). Both obstructive and nonobstructive HCM
were independent predictors of cardiovascular events
compared with the labile group, after adjusting for age
and sex. The hazard ratios and 95% conﬁdence intervals
were 3.41 (2.07–5.63) for obstructive HCM and 1.99
(1.19–3.33) for nonobstructive HCM (model 2; Table 4). In
univariate Cox regression, age, male sex, NYHA class,
history of sustained VT/VF, LA diameter, E/e0, and
metabolic equivalents were predictive of future composite
events (Table 5). After additional adjustments for these
potential confounding parameters, the HCM subgroups
remained independently associated with clinical outcomes
(model 3; Table 4).
Table 2. Echocardiographic and Treadmill Exercise Parameters in Patients Stratiﬁed by HCM Classiﬁcation
Parameters
Nonobstructive
HCM (N=214)
Labile
HCM (N=261)
Obstructive
HCM (N=230) P Value
Echocardiography
Left atrium diameter, mm 407 417 447 <0.001
Septal thickness, mm 216 205 225 0.007*
Posterior wall, mm 113 124 133 <0.001*
LVEF, % 658 667 668 0.128
E/A 1.50.9 1.30.7 1.30.7 0.039*
E/e0 15.49.1 16.78.5 24.012.7 <0.001*
LVOT gradient at rest, mm Hg 84 1610 6631 <0.001*
LVOT gradient at stress, mm Hg 176 7241 11845 <0.001*
Treadmill exercise
Bruce protocol, n (%) 177 (83) 215 (82) 143 (62) <0.001
Exercise time, s† 560207 563220 490171 <0.001*
METs 10.74.0 10.44.4 8.33.6 <0.001*
Resting SBP, mm Hg 12927 13518 13318 <0.001*
Resting DBP, mm Hg 7711 7912 7611 0.033
Resting heart rate, bpm 6714 6513 6714 0.050*
Peak SBP, mm Hg 15936 16536 15235 <0.001*
Peak DBP, mm Hg 8018 8218 7919 0.059*
Peak heart rate, bpm 14830 14528 13327 <0.001
Data are given as meanSD unless otherwise indicated. Bpm indicates beats/min; DBP, diastolic blood pressure; E/A, ratio of early diastolic mitral ﬂow velocity/late diastolic mitral ﬂow
velocity; E/e0 , ratio of early diastolic mitral ﬂow velocity/early diastolic mitral septal annulus motion velocity; HCM, hypertrophic cardiomyopathy; LVEF, left ventricular ejection fraction;
LVOT, left ventricle outﬂow tract; MET, metabolic equivalent; and SBP, systolic blood pressure.
*Analysis was performed using a Kruskal-Wallis test.
†Data from 535 patients who performed a treadmill test using the Bruce protocol.
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Discussion
In this large single-center HCM cohort, we present several
novel and clinically important insights into the most common
inherited cardiac disease. To our knowledge, there are no
clinical outcome data using the modern hemodynamic
classiﬁcation of HCM into nonobstructive, labile, and obstruc-
tive HCM.
A recent study in 2016 described HCM-related mortality
among patients with nonobstructive HCM as low (0.5% per
year), with a 10-year survival rate of 97%, which was similar to
expected all-cause mortality in an age- and sex-matched US
population. However, focusing on mortality rate alone may
underestimate the substantial morbidity burden in a subset of
patients with nonobstructive HCM.22 In contrast with most
literature to date, we ﬁnd that patients with nonobstructive
HCM are at signiﬁcantly higher risk than previously sus-
pected. Conversely, despite the obstructive hemodynamics,
patients with labile-obstructive HCM experience a generally
benign clinical course. Concordant with previous studies,
resting LVOT obstruction (LVOTO) is associated with the
highest risk of developing our composite end point. Specif-
ically, we found an increased risk of arrhythmia, HF, and
death. Our ﬁndings may stimulate a critical rethinking of how
best to manage nonobstructive and labile-obstructive HCM. In
addition, our study provides some granularity on the nature of
speciﬁc clinical outcomes across the 3 HCM groups. Patients
with obstructive HCM with signiﬁcant LVOT pressure gradi-
ents predominantly experienced AF, HF, and death. Patients
with nonobstructive HCM had more ventricular arrhythmic
(sustained VT/VF) events.
Dynamic LVOTO has long been considered the primary
driver of symptoms and complications in HCM. Landmark
publications indicated that resting LVOT gradient ≥30 mm Hg
is a strong independent predictor for symptoms, progression
of HF, and death.7 Our data further support the high-risk
nature of obstructive HCM, and this ﬁnding validates that our
cohort is generally similar to previously published large HCM
cohorts. Obstructive HCM was associated with the worst
diastolic function and the largest LA size. The relationship
between diastolic dysfunction and LA size has been demon-
strated in various studies,23,24 and LA volume may be taken
as a reﬂection of severity and chronicity of diastolic dysfunc-
tion.25 In the Framingham study, LA enlargement was
demonstrated as a predictor for nonrheumatic AF in the
general population,26 and was also the most sensitive and
speciﬁc parameter associated with paroxysmal AF in patients
with HCM.27
Given the higher rates of symptoms and complications, it is
understandable that clinicians pay most attention to patients
with obstructive HCM. However, this focus on high gradients
seems to have inexorably led to an underappreciation of the
adverse outcomes in patients with nonobstructive HCM.28 A
recent study with 573 patients reported the clinical course
was largely favorable in nonobstructive HCM, with low risk of
worsening HF and low mortality.22 Although the annual
mortality for nonobstructive HCM was <1%, the rate of
disease-related events, many of them potentially life threat-
ening, was high.29 Thus, the data in that study corroborate our
data on the high rates of ventricular arrhythmia in patients
with nonobstructive HCM. In a report by Hebl et al, the
prevalence of ICD placed preceding the index visit was also up
Figure 1. Cumulative incidence of individual cardiovascular outcomes in nonobstructive (A), labile (B), and obstructive (C) hypertrophic
cardiomyopathy (HCM) groups. AF indicates atrial ﬁbrillation; and VT/VF, ventricular tachycardia/ventricular ﬁbrillation.
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to 11% of the cohort, reﬂecting the heavy burden of
ventricular arrhythmia.30 Our observation that particular
patients with nonobstructive HCM are at high risk is the key
message of this article, and hopefully it stimulates the wider
HCM community to examine their own databases to either
conﬁrm or validate our observation in this large cohort.
Furthermore, our ﬁndings suggest that evaluation of
nonobstructive HCM should be more nuanced and delibera-
tive. More important, lack of high gradients should not lull
clinicians into reassuring patients with nonobstructive hemo-
dynamics without further investigation.
Our clinical outcome data in nonobstructive HCM have a
substantial biological and pathophysiologic basis. Myocardial
ﬁbrosis, resulting from recurrent microvascular ischemia, is
Figure 2. Kaplan-Meier 10-year event-free survival analysis for atrial ﬁbrillation (A), sustained ventricular tachycardia/ﬁbrillation (B), heart
failure (C), all-cause death (D), and composite cardiovascular events (E) stratiﬁed by nonobstructive, labile, and obstructive hypertrophic
cardiomyopathy (HCM) groups.
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believed to be the substrate for potentially life-threatening
ventricular arrhythmias in patients with HCM.31 Previous
studies have described a strong association between non-
sustained VT on ambulatory Holter monitoring and the
presence of late gadolinium enhancement on cardiac mag-
netic resonance imaging that represents ﬁbrosis.32,33 In
addition, late gadolinium enhancement was associated with
HF symptoms and was a strong determinant of LV dysfunction
in HCM.34 In our previous report, we connected these
pathological characteristics with nonobstructive HCM by
demonstrating that more patients with nonobstructive HCM
had a large ﬁbrosis burden (late gadolinium enhancement,
>20% of LV mass) and microvascular ischemia.12 In that
study, even with a substantially smaller cohort size, we
already saw a pattern of worse arrhythmic events in
nonobstructive HCM. Others have shown that the prevalence
and extent of scar (late gadolinium enhancement) were larger
in nonobstructive HCM.22 Thus, our data and other published
evidence suggest that myocardial ﬁbrosis, microvascular
ischemia, and a host of unidentiﬁed factors likely mediate
the generation of malignant ventricular arrhythmias in
nonobstructive HCM.
Our data lay out, for the ﬁrst time, that all obstructive
hemodynamics are not bad. Those with resting obstruction
(ﬁxed obstructive HCM) have poor long-term outcomes.
However, those with obstruction only on provocation (labile
Table 3. HRs and 95% CIs for Individual Cardiovascular Events During 10 Years of Follow-Up by Classiﬁcation of HCM
Classiﬁcation
Model 1 Model 2
HR (95% CI) P Value HR (95% CI) P Value
Atrial fibrillation
Labile HCM 1 1
Nonobstructive HCM 0.90 (0.37–2.17) 0.815  
Obstructive HCM 3.43 (1.73–6.81) <0.001 3.22 (1.61–6.47) 0.001
Sustained ventricular tachycardia/ventricular fibrillation
Labile HCM 1 1
Nonobstructive HCM 4.64 (1.56–13.82) 0.006 4.69 (1.57–13.97) 0.006
Obstructive HCM 1.89 (0.55–6.46) 0.310  
Heart failure
Labile HCM 1 1
Nonobstructive HCM 1.97 (0.87–4.47) 0.103  
Obstructive HCM 2.10 (0.94–4.71) 0.072  
All-cause death
Labile HCM 1 1
Nonobstructive HCM 1.89 (0.63–5.66) 0.254  
Obstructive HCM 235 (0.82–6.78) 0.113  
The labile HCM was set as a reference group. Model 1, crude ratio; and model 2, adjusted for age and sex. CI indicates conﬁdence interval; HCM, hypertrophic cardiomyopathy; and HR,
hazard ratio.
Table 4. HRs and 95% CIs for Composite Cardiovascular Events During 10 Years of Follow-Up by Classiﬁcation of HCM
Classiﬁcation Events/Cases
Model 1 Model 2 Model 3
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Composite outcome
Nonobstructive HCM 43/214 2.00 (1.19–3.34) 0.008 1.99 (1.19–3.33) 0.009 1.94 (1.09–3.45) 0.024
Labile HCM 22/261 1 1 1
Obstructive HCM 56/230 3.73 (2.27–6.11) <0.001 3.41 (2.07–5.63) <0.001 2.80 (1.64–4.80) <0.001
Model 1, crude ratio; model 2, adjusted for age and sex; and model 3, adjusted for age, sex, New York Heart Association functional class, history of sustained ventricular tachycardia/
ventricular ﬁbrillation, left atrial diameter, ratio of early diastolic mitral ﬂow velocity/early diastolic mitral septal annulus motion velocity, and metabolic equivalents. CI indicates conﬁdence
interval; HCM, hypertrophic cardiomyopathy; and HR, hazard ratio.
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HCM) do extremely well, with low rates of adverse outcomes.
Each of the 3 HCM subgroups has distinctive clinical
outcomes. The clinical characteristics and distribution of
outcomes are summarized in Table 6.
Maron et al reported that more than half of patients with
HCM without resting gradients developed LVOTO on exer-
cise.5 Of this labile-obstruction subset, 43% were symp-
tomatic (NYHA class II or III), but 57% were asymptomatic. The
observation that most patients (ie, 60%) who developed
moderate-to-severe HF symptoms did, in fact, generate
hemodynamically signiﬁcant gradients only with exercise
brought the hypothesis that mechanical outﬂow obstruction
related to exercise in such patients could prove to be of
pathophysiological signiﬁcance over time.5 On the basis of
this ﬁnding, the 2011 American College of Cardiology/
American Heart Association guidelines give exercise echocar-
diography a class IIa recommendation for detection and
quantiﬁcation of dynamic LVOTO in patients with HCM
without resting gradients, irrespective of symptoms.19 In
contrast, the 2014 European Society of Cardiology guidelines
only recommend exercise stress echocardiography in symp-
tomatic patients if bedside maneuvers fail to induce an LVOTO
≥50 mm Hg, but they do not recommend exercise stress
echocardiography in asymptomatic patients unless the pres-
ence of an LVOT gradient is relevant to lifestyle advice and
decisions on medical treatment.18 The present study may help
place in perspective the discrepancy between the HCM
recommendations offered by the American College of Cardi-
ology/American Heart Association versus the European
Society of Cardiology. In our data, the overall risks among 3
different hemodynamic classiﬁcations did not change,
whether they were symptomatic or not. Even among asymp-
tomatic patients in our study, labile HCM still carried a better
prognosis than the other 2 groups. The difference in adverse
outcomes between nonobstructive and labile HCM, regardless
of symptoms, underscores the importance of identifying
provoked LVOT pressure gradients, which may actually
indicate a favorable outcome.
Our data highlight 2 important points that may affect how
both HCM guidelines are interpreted. First, on the basis of our
data, there is no evidence that labile HCM is associated with
adverse outcomes (within a mean follow-up of 3 years). This
is contrary to the current guideline premise that labile LVOTO
might generally lead to clinical deterioration. In the present
study, the patients with labile LVOTO had more favorable
outcomes than those with nonobstructive disease. Second, if
this association is corroborated by subsequent studies, then
there would be a strong argument for integration of routine
exercise stress echocardiography into risk stratiﬁcation
protocols to identify latent LVOTO. The caveat, however, is
critical: latent LVOTO must ﬁrst be identiﬁed as a signiﬁcant
independent predictor of favorable outcome in additional,
large-scale studies with longer-term follow-up. In the present
study, we found that patients with HCM with labile LVOTO had
more favorable outcomes than those with nonobstructive
disease. If this association is corroborated by subsequent
Table 5. Determinants of Cardiovascular Events During
10 Years of Follow-Up: Univariate Cox Regression Analysis
Univariate Factors HR (95% CI) P Value
Age, per y 1.02 (1.00–1.03) 0.017
Male sex 0.65 (0.45–0.93) 0.017
Body mass index, per unit 1.00 (0.98–1.03) 0.954
NYHA functional class 1.52 (1.21–1.91) <0.001
History of hypertension 1.00 (0.70–1.43) 0.985
History of hyperlipidemia 0.96 (0.67–1.37) 0.810
History of sustained VT/VF 2.90 (1.52–5.54) 0.001
Abnormal blood pressure response 0.97 (0.64–1.49) 0.896
Left atrial diameter, per mm 1.05 (1.03–1.07) <0.001
Septal thickness, per mm 1.02 (0.99–1.06) 0.126
Posterior wall thickness, per mm 1.03 (0.99–1.07) 0.149
E/A, per unit 1.16 (0.94–1.42) 0.160
E/e0, per unit 1.03 (1.02–1.04) <0.001
Metabolic equivalents, per unit 0.90 (0.86–0.95) <0.001
Resting systolic blood pressure,
per mm Hg
0.99 (0.99–1.00) 0.220
Resting diastolic blood pressure,
per mm Hg
0.99 (0.97–1.00) 0.074
Peak systolic blood pressure,
per mm Hg
1.00 (0.99–1.00) 0.161
CI indicates conﬁdence interval; E/A, ratio of early diastolic mitral ﬂow velocity/late
diastolic mitral ﬂow velocity; E/e0 , ratio of early diastolic mitral ﬂow velocity/early
diastolic mitral septal annulus motion velocity; HR, hazard ratio; NYHA, New York Heart
Association; and VT/VF, ventricular tachycardia/ventricular ﬁbrillation.
Table 6. Summary of Clinical Outcomes of the 3 HCM
Hemodynamic Spectrums
Outcomes Nonobstructive HCM Labile HCM Obstructive HCM
Need for SRT  + ++
Clinical outcomes
AF + + +++
VT/VF +++ ++ +
Heart failure ++ + ++
Death + +/ +
Overall risk Intermediate Low High
The left ventricular outﬂow tract pressure gradients were as follows: nonobstructive
HCM, at rest, <30 mm Hg, and provoked, <30 mm Hg; labile HCM, at rest, <30 mm Hg,
and provoked, ≥30 mm Hg; and obstructive HCM, at rest, ≥30 mm Hg, and provoked,
≥30 mm Hg. + indicates low risk; ++, intermediate risk; +++, high risk; , not
applicable; AF, atrial ﬁbrillation; HCM, hypertrophic cardiomyopathy; SRT, septal
reduction therapy; and VT/VF, ventricular tachycardia/ventricular ﬁbrillation.
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studies, there would be an argument for routine exercise
stress echocardiography in all patients with HCM and
particularly in those with resting gradients <30 mm Hg,
regardless of symptoms. However, labile HCM will need to
be identiﬁed as a signiﬁcant independent predictor of
favorable outcome in additional large-scale studies with
longer-term follow-up.
Limitations of the Study
This was a single, tertiary, referral center cohort. Hence, a
referral bias might exist. However, this cohort is no different
than those reported in most HCM-related publications.7,35
There is a chance that asymptomatic patients were not
referred to us. However, this bias should uniformly affect all
groups; thus, we believe it should not unduly affect the
results. This is an observational study, and we were not
equipped to address why patients with nonobstructive HCM
may develop more ventricular arrhythmias and why patients
with obstructive HCM have more atrial arrhythmias. Our
previous work and the work of others led us to speculate on
potential mechanisms that may underlie the development of
these complications in particular HCM subgroups.12,22 We did
not include any genetics data in our analysis because
genotyping is not considered for clinical diagnosis of
HCM.19 There is an abundance of literature on the lack of a
clear connection between genotype and phenotype or clinical
outcomes in HCM.36 Although we had a relatively large
number of patients with 10 years of follow-up, the median
follow-up was 3 years. There is still a need for replication of
our ﬁndings with large-scale studies with longer follow-up. We
used a composite clinical end point, like other seminal articles
on HCM.37,38 Several articles document the low rates of death
and adverse events in HCM.22,39 Moreover, using death as the
only end point ignores the serious nonfatal complications in
HCM that affect quality of life. Also, as astutely pointed out in
a recent editorial,29 if high-risk patients were not identiﬁed
and intervened on in a timely manner, there would be
signiﬁcantly more deaths. We humbly submit that a composite
clinical end point is clinically meaningful and useful in the
population with HCM. The high rates of appropriate deﬁbril-
lator discharges in our and other studies underscore this
latter point.
Conclusion
Despite low annual mortality rates, patients with nonobstruc-
tive HCM have high rates of adverse clinical events, almost
equivalent to those with obstructive HCM. Patients with
nonobstructive HCM warrant thorough vetting, with a focus on
the need for deﬁbrillator therapy. Patients with obstructive
HCM have the worst symptoms and high rates of adverse
events. They merit aggressive treatment. Patients with labile
HCM have the best prognosis and may need less aggressive
management, with the recognition that all patients with HCM
should be objectively risk stratiﬁed. Further large-scale
studies with longer follow-up are needed to support our
results.
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